ArticleGeroScience2025
Immunosenescence accelerates atherosclerosis development in AAV-PCSK9 mouse model.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.Aging cell · 2026Article
- Mouse Models of Atherosclerosis: What They Teach Us, What They Miss, and When to Use Them.Bioengineering (Basel, Switzerland) · 2026Review
- B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts.Immunological reviews · 2026Review
- Age-associated B-cells across the rheumatoid arthritis continuum: from early immunopathogenesis to comorbidities.Frontiers in aging · 2026Review
- Correlation Analysis of the New Inflammatory Composite Index with the Degree of Coronary Artery Lesions in Elderly Patients.Clinical interventions in aging · 2026Article
- Experimental atherosclerosis models in small animals (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aging is a dominant risk factor for atherosclerotic cardiovascular disease and is associated with compositional and functional changes in our immune system, called immunosenescence. To gain insights into the impact of immunosenescence on atherosclerosis, we investigated plaque development and the immune landscape in an AAV-PCSK9 mouse model. Young (3 months) and aged (18 months) male C57Bl/6 mice received a single i.v. injection of a recombinant adeno-associated virus encoding murine PCSK9 (rAAV8-D377Y-mPCSK9) and were fed a Western-type diet (WTD) for 10 weeks to induce atherosclerosis. At sacrifice, cholesterol and serum PCSK9 levels showed no difference. Atherosclerosis development in the aortic root was significantly enhanced with 59% in aged compared to young mice. Additionally, plaques in aged mice showed a more advanced phenotype, with an increased collagen/macrophage ratio. While the T cell percentage declined in the periphery and lymphoid organs upon aging, leukocytes, including T- and B cells, increased within the aged aortic arch. Moreover, we observed a shift towards effector (memory) subsets, including Th1 cells and Tregs, with elevated cytokine production and a senescent phenotype within the T cell compartment of aged mice. We also observed increased percentages of splenic age-associated B cells, regulatory B cells and plasma cells in aged mice, which coincided with increased levels of circulating antibodies. In conclusion, aged WTD-fed AAV-PCSK9 mice displayed pro-atherogenic immune alterations, including elevated plaque inflammation, increased cellular senescence and impaired humoral immune responses, contributing to accelerated atherosclerosis development compared to young mice. Targeting or reversing age-associated immunity could represent a promising strategy to combat atherosclerotic cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.